# Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

> **NCT01630018** · PHASE2 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 141 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Topotecan
- **DRUG:** Belotecan

## Key facts

- **NCT ID:** NCT01630018
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2016-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01630018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01630018, "Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01630018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*